Phase
Condition
Multiple Myeloma
Cervical Cancer
Lymphoma
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Histologically confirmed malignancy
No more than 5 days since placement of central venous catheter for administration ofchemotherapy
Expected length of catheter use at least 16 weeks
18 and over
Performance status: ECOG 0-2
Life expectancy: At least 16 weeks
Hematopoietic:
Platelet count at least 100,000/mm3
Absolute neutrophil count at least 1,500/mm3
No known coagulopathy
Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) except in caseof Gilbert's syndrome
AST no greater than 3 times ULN (no greater than 5 times ULN in case of livermetastases)
PT/PTT no greater than 1.5 times ULN Renal:
Creatinine no greater than 2 times ULN Cardiovascular:
HIV negative
Must weigh at least 90 pounds
At least 3 months since prior eye, ear, or CNS surgery Other:
At least 30 days since prior aspirin, dipyridamole, unfractionated heparin, other lowmolecular weight heparins, or other anticoagulation therapy (except heparin flushing)
Exclusion
Exclusion Criteria:
uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure
myocardial infarction in past 6 months
uncontrolled cardiac arrhythmia Other:
known hypersensitivity (including heparin induced thrombocytopenia) to dalteparin,heparin, or other low molecular weight heparins
active uncontrolled infection, including existing catheter related infection
CNS trauma in past 3 months
retinal detachment in past 6 months
mental incapacitation or psychiatric illness that would preclude study compliance
other serious concurrent disease that would preclude study participation
active gastrointestinal or genitourinary tract bleeding
intracranial or intraocular hemorrhage in past year
concurrent high dose chemotherapy with stem cell transplantation
concurrent induction/consolidation chemotherapy for leukemia
concurrent high dose chemotherapy with stem cell transplantation
Study Design
Study Description
Connect with a study center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California 90095-1781
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.